Stephens Begins Coverage on Nurix Therapeutics (NASDAQ:NRIX)

Stephens initiated coverage on shares of Nurix Therapeutics (NASDAQ:NRIX – Free Report) in a research note published on Tuesday morning, MarketBeat.com reports. The brokerage issued an overweight rating and a $20.00 price target on the stock. NRIX has been the subject of several other research reports. Morgan Stanley lifted their price objective on shares of […]

Related Keywords

Canada ,China ,Entrypoint ,British Columbia ,Houte Hans Van ,Robertw Baird ,Nurix Therapeutics Company Profile ,Nurix Therapeutics Inc ,Royal Bank ,Needham Company ,International Assets Investment Management ,China Universal Asset Management Co ,Quest Partners ,Wells Fargo Company ,Morgan Stanley ,Entrypoint Capital ,Proshare Advisors ,Nurix Therapeutics ,Free Report ,Moderate Buy ,Get Free Report ,Hans Van ,Universal Asset Management ,Point Capital ,Share Advisors ,Casitasb Lineage ,Nurix Therapeutics Daily ,